NeoGenomics (NEO) Q2 Earnings Report Preview: What To Look For
NeoGenomics (NASDAQ: NEO) is set to report Q2 earnings Tuesday. The company last quarter reported $186.7M revenue, up 11.1% year over year, with EPS in line and full-year revenue guidance meeting expectations. Analysts expect Q2 revenue growth of 8.8% y/y. NEO is down 2.5% over the past month, with an average analyst price target of $16.78 versus $13.89.
How this was made
The 30-second read
Why it matters
The key decision point is the reported Q2 revenue growth versus the 8.8% YoY consensus and whether management guidance changes the forward trajectory after a history of revenue estimate misses.
Market read
With NEO down 2.5% over the last month and Street reconfirming estimates, the earnings print is likely to drive near-term repricing if revenue or guidance deviates from consensus.
What to watch
The preview emphasizes revenue misses but does not discuss cost structure, guidance details, or any specific driver (test volumes, reimbursement, mix) that could explain whether the next print is likely to be a miss or beat.
Background
NeoGenomics is scheduled to report Q2 results Tuesday afternoon; the article frames expectations using prior quarter performance and recent estimate behavior.
Ticker impact
Article previews NeoGenomics earnings Tuesday, citing consensus revenue growth of 8.8% and recent underperformance versus revenue estimates.
Moderate volatility around the print, with upside/downside skew tied to revenue vs the 8.8% YoY expectation and any guidance commentary.
The text provides specific consensus growth (8.8% YoY) and notes multiple recent revenue misses, which increases sensitivity to the reported revenue number and forward outlook.
Market effects
Uses peer results (Quest, Tenet) as a read-across for healthcare diagnostics/providers, but provides no new sector policy or demand data.
No explicit regional linkage beyond US healthcare services sentiment.
No global macro or cross-border catalyst mentioned.
Counterpoint
If peers’ beats translate into broader demand strength, NEO could outperform even with only modest growth, especially if margins/EPS hold up.
Key entities
- companyNeoGenomics
Oncology diagnostics company reporting Q2 earnings Tuesday afternoon; consensus expects 8.8% YoY revenue growth.
- peerQuest Diagnostics
Peer cited as having delivered Q2 revenue growth of 10.2% and a beat versus expectations.
- peerTenet Healthcare
Peer cited as having reported Q2 revenues up 6.8% and topping estimates.
